NCT01188863View on ClinicalTrials.gov

Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

October 31, 2010

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

300 mg LX4211 (150 mg tablets)

Single oral dose of two 150 mg tablets LX4211

DRUG

300 mg LX4211 (50 mg tablets)

Single oral dose of six 50 mg tablets LX4211

DRUG

300 mg LX4211 (liquid)

Single 30 mL dose of liquid oral solution LX4211 (10 mg/mL)

Trial Locations (1)

78209

Lexicon Investigational Site, San Antonio

Sponsors
All Listed Sponsors
lead

Lexicon Pharmaceuticals

INDUSTRY